Literature DB >> 24261722

Cutaneous porphyrias part I: epidemiology, pathogenesis, presentation, diagnosis, and histopathology.

Mary E Horner1, Ali Alikhan, Suzanne Tintle, Silvia Tortorelli, Dawn Marie R Davis, Jennifer L Hand.   

Abstract

The porphyrias are a group of disorders characterized by defects in the heme biosynthesis pathway. Many present with skin findings including photosensitivity, bullae, hypertrichosis, and scarring. Systemic symptoms may include abdominal pain, neuropsychiatric changes, anemia, and liver disease. With advances in DNA analysis, researchers are discovering the underlying genetic causes of the porphyrias, enabling family members to be tested for genetic mutations. Here we present a comprehensive review of porphyria focusing on those with cutaneous manifestations. In Part I, we have included the epidemiology, pathogenesis, presentation, diagnosis, and histopathology. Treatment and management options will be discussed in Part II.
© 2013 The International Society of Dermatology.

Entities:  

Mesh:

Year:  2013        PMID: 24261722     DOI: 10.1111/ijd.12305

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  8 in total

1.  [Porphyrias : Metabolic disorders of heme biosynthesis].

Authors:  J Frank
Journal:  Hautarzt       Date:  2016-03       Impact factor: 0.751

Review 2.  [Congenital erythropoietic porphyria : An update].

Authors:  C Wenner; N J Neumann; J Frank
Journal:  Hautarzt       Date:  2016-03       Impact factor: 0.751

3.  Genetic ancestry of patients with porphyria cutanea tarda in a country with mixed races: a cross-sectional study (Rio de Janeiro - Brazil).

Authors:  Isabella Brasil Succi; Luís Cristóvão Pôrto; Patricia Mariana Gonçalves da Rocha Porto Domingues; João Carlos Macedo Fonseca
Journal:  An Bras Dermatol       Date:  2018 Jan-Feb       Impact factor: 1.896

Review 4.  Protoporphyrin IX: the Good, the Bad, and the Ugly.

Authors:  Madhav Sachar; Karl E Anderson; Xiaochao Ma
Journal:  J Pharmacol Exp Ther       Date:  2015-11-20       Impact factor: 4.030

5.  Acitretin mitigates uroporphyrin-induced bone defects in congenital erythropoietic porphyria models.

Authors:  Juliana Bragazzi Cunha; Jared S Elenbaas; Dhiman Maitra; Ning Kuo; Rodrigo Azuero-Dajud; Allison C Ferguson; Megan S Griffin; Stephen I Lentz; Jordan A Shavit; M Bishr Omary
Journal:  Sci Rep       Date:  2021-05-05       Impact factor: 4.379

6.  Variegate Porphyria Triggered by Acute Hepatitis A Infection.

Authors:  Daniel Micallef; Charlton Agius; Charles Mallia-Azzopardi; Gerald Buhagiar; Lawrence Scerri
Journal:  Eur J Case Rep Intern Med       Date:  2020-09-22

7.  Porphyria Cutanea Tarda Masquerading as Epidermolysis Bullosa Acquisita: A Report of Two Cases.

Authors:  Kristyn Deen; Jason Wu
Journal:  Case Rep Dermatol       Date:  2015-07-03

Review 8.  Unraveling the Role of Heme in Neurodegeneration.

Authors:  Deborah Chiabrando; Veronica Fiorito; Sara Petrillo; Emanuela Tolosano
Journal:  Front Neurosci       Date:  2018-10-09       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.